Opportunity Information: Apply for PAR 20 212
The NIH funding opportunity PAR-20-212, titled "Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)," is designed to help early career scientists launch more independent HIV/AIDS research programs that rely on nonhuman primate models. It uses the R21 mechanism, which is typically meant for exploratory, early-stage projects that can generate key proof-of-concept data, establish feasibility, or open up a new line of inquiry. The central focus is preclinical and translational HIV/AIDS research where NHP models are essential to the scientific approach, with the broader intent of helping investigators build momentum toward larger, longer-term awards such as an R01.
A defining feature of this announcement is that it specifically targets Early Stage Investigators (ESIs). To fit the intended applicant profile, the principal investigator should be within 10 years of their terminal degree or completion of residency training, and they must have accumulated at least two years of postdoctoral experience. The program is meant to provide a meaningful stepping-stone between mentored training and full research independence. In practical terms, NIH is signaling that this award should help an ESI establish a distinct research direction, strengthen their publication and preliminary-data portfolio, and become more competitive for future independent funding.
The science scope centers on HIV/AIDS translational studies conducted in nonhuman primate systems as preclinical models. While the solicitation language is broad, it anchors the supported work to the NIH HIV research priorities described in the FY2019/2020 NIH Strategic Plan for HIV and HIV-Related Research. That includes projects aimed at HIV prevention and cure strategies, next-generation therapeutics, and deeper understanding of HIV-associated comorbidities, coinfections, and complications. It also explicitly welcomes cross-cutting efforts that build capacity, which can include strengthening research resources, approaches, or pipelines that make NHP-enabled HIV research more robust and sustainable. The emphasis on NHP models implies the proposed work should be something that either cannot be done or would be far less informative in simpler systems, and that the NHP work is integral to answering the translational question rather than being incidental.
This opportunity is marked "Clinical Trial Not Allowed," meaning applicants cannot propose an NIH-defined clinical trial under this FOA. The work is expected to be preclinical, even if it is translational in intent (for example, evaluating prevention concepts, immune strategies, or therapeutic approaches in NHP models before human testing). Applicants need to structure aims, outcomes, and study design accordingly, keeping the project on the preclinical side of the translational pipeline.
Eligibility is broad across U.S.-based organizations. Eligible applicants include a range of government entities (state, county, city/township governments, special districts), educational institutions (public/state-controlled and private institutions of higher education), independent school districts, tribal governments (federally recognized) and certain tribal organizations, public housing authorities/Indian housing authorities, nonprofits (with or without 501(c)(3) status), for-profit organizations (other than small businesses), and small businesses. The announcement also highlights several institution types as eligible, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations and eligible federal agencies. U.S. territories or possessions are also included among eligible applicant categories.
At the same time, there are clear geographic and organizational restrictions related to foreign involvement. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply. In addition, non-domestic components of U.S. organizations are not eligible to apply, and foreign components (as defined by the NIH Grants Policy Statement) are not allowed. In effect, the applicant organization and the supported components of the work must remain domestic under NIH policy for this program.
From an administrative standpoint, the opportunity is offered by the National Institutes of Health under CFDA 93.847, categorized under health (and listed in the source data as "Food and Nutrition, Health"). The funding instrument is a grant, and the opportunity category is discretionary. The record shows a creation date of June 16, 2020, with an original closing date of September 7, 2022. The publicly provided fields in the source data do not specify an award ceiling or expected number of awards, so applicants would typically look to the full FOA text and NIH policy for the standard R21 budget structure and any institute- or program-specific guidance tied to this announcement.
Overall, this FOA is best understood as a targeted on-ramp for ESIs who are ready to lead a distinct, NHP-based HIV/AIDS preclinical research project that aligns with NIH HIV strategic priorities, produces impactful early results, and positions the investigator for the next stage of independent funding.Apply for PAR 20 212
- The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
- This funding opportunity was created on 2020-06-16.
- Applicants must submit their applications by 2022-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH PAR-20-212 (R21) Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate Models
What is PAR-20-212?
PAR-20-212 is an NIH funding opportunity titled "Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)." It supports early career scientists conducting HIV/AIDS research where nonhuman primate models are essential to the scientific approach.
What is the main purpose of this funding opportunity?
The main purpose is to help Early Stage Investigators (ESIs) launch more independent HIV/AIDS research programs using NHP models. It is intended to serve as a stepping-stone between mentored training and full research independence and to help investigators build momentum toward larger, longer-term awards (such as an R01).
What grant mechanism does this opportunity use?
This opportunity uses the NIH R21 mechanism, which is typically used for exploratory and early-stage projects that generate proof-of-concept data, establish feasibility, or open up new lines of inquiry.
Who is this opportunity designed for?
It is specifically targeted to Early Stage Investigators (ESIs), meaning early career scientists who are building toward research independence and are ready to lead a distinct HIV/AIDS research direction that relies on NHP models.
What are the Early Stage Investigator (ESI) expectations described here?
The principal investigator (PI) should be within 10 years of their terminal degree or completion of residency training and must have accumulated at least two years of postdoctoral experience. The overall goal is to support a meaningful transition toward independence.
What type of research does PAR-20-212 support?
The focus is on preclinical and translational HIV/AIDS research conducted in nonhuman primate systems as preclinical models. Projects should align with NIH HIV research priorities described in the FY2019/2020 NIH Strategic Plan for HIV and HIV-Related Research.
What topic areas are included within the scientific scope?
Based on the description provided, the scope includes HIV prevention and cure strategies, next-generation therapeutics, and research into HIV-associated comorbidities, coinfections, and complications. It also welcomes cross-cutting efforts that build capacity, such as strengthening resources, approaches, or pipelines that improve the robustness and sustainability of NHP-enabled HIV research.
Do projects have to use nonhuman primate (NHP) models?
Yes. The central focus is HIV/AIDS research where NHP models are essential to the scientific approach. The NHP work should be integral to answering the translational question rather than incidental, and it should be something that cannot be done (or would be far less informative) in simpler systems.
Is this opportunity for clinical trials?
No. The announcement is marked "Clinical Trial Not Allowed," meaning applicants cannot propose an NIH-defined clinical trial under this FOA. The supported work is expected to be preclinical, even if it is translational in intent.
Can the research still be translational if clinical trials are not allowed?
Yes. The description explicitly indicates the work may be translational in intent (for example, evaluating prevention concepts, immune strategies, or therapeutic approaches in NHP models) as long as it remains on the preclinical side prior to human testing.
How should applicants structure their project given the "Clinical Trial Not Allowed" requirement?
Applicants should structure aims, outcomes, and study design in a way that keeps the project preclinical under NIH definitions, consistent with the FOA restriction that clinical trials are not allowed.
What kinds of organizations are eligible to apply?
Eligibility is broad across U.S.-based organizations. Eligible applicants include various government entities (state, county, city/township, special districts), educational institutions (public/state-controlled and private higher education), independent school districts, federally recognized tribal governments and certain tribal organizations, public housing authorities/Indian housing authorities, nonprofits (with or without 501(c)(3) status), for-profit organizations (other than small businesses), and small businesses.
Are specific institution types highlighted as eligible?
Yes. The opportunity highlights eligibility for institution types including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs). It also notes faith-based or community-based organizations and eligible federal agencies.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are included among the eligible applicant categories described.
Are foreign (non-U.S.) organizations eligible to apply?
No. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply under this opportunity.
Can a U.S. organization include a foreign component in the project?
No. Non-domestic components of U.S. organizations are not eligible to apply, and foreign components (as defined by the NIH Grants Policy Statement) are not allowed. The applicant organization and supported components of the work must remain domestic under NIH policy for this program.
Which federal program listing is associated with this opportunity?
The opportunity is associated with CFDA 93.847 and is offered by the National Institutes of Health (NIH).
What type of funding instrument is this?
The funding instrument is a grant, and the opportunity category is discretionary.
What are the key dates mentioned for this opportunity?
The record shows a creation date of June 16, 2020, and an original closing date of September 7, 2022.
Does the provided information specify the award ceiling or number of awards?
No. The publicly provided fields described do not specify an award ceiling or the expected number of awards.
What is the intended outcome or longer-term impact for investigators who receive this award?
The intent is to help an ESI establish a distinct research direction, strengthen publications and preliminary data, and become more competitive for future independent funding, including larger and longer-term mechanisms such as an R01.
What does NIH appear to be emphasizing about the role of NHP models in proposed projects?
The emphasis is that NHP models should be essential to the translational question being asked. The NHP work should not be incidental; it should materially enable the scientific approach in a way that simpler systems cannot.
How does this FOA relate to NIH-wide HIV priorities?
The supported work is anchored to NIH HIV research priorities described in the FY2019/2020 NIH Strategic Plan for HIV and HIV-Related Research, including prevention, cure strategies, therapeutics, and HIV-associated comorbidities, coinfections, and complications.
Browse more opportunities from the same category: Food and Nutrition, Health
Next opportunity: Request for Information (RFI): Engaging States to Advance State Energy Office Priorities
Previous opportunity: U.S.-South Africa Space Camp program
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 20 212
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 20 212) also looked into and applied for these:
| Funding Opportunity |
|---|
| Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed) Apply for RFA DK 20 016 Funding Number: RFA DK 20 016 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Biomarkers of Dietary Intake and Exposure Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA DK 20 007 Funding Number: RFA DK 20 007 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Biomarkers of Dietary Intake and Exposure (U2C Clinical Trial Required) Apply for RFA DK 20 005 Funding Number: RFA DK 20 005 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required) Apply for RFA DK 20 012 Funding Number: RFA DK 20 012 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required) Apply for RFA DK 20 011 Funding Number: RFA DK 20 011 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional) Apply for RFA DK 20 021 Funding Number: RFA DK 20 021 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $250,000 |
| Liver Cirrhosis Network: Clinical Research Centers (U01 Clinical Trial Required) Apply for RFA DK 20 003 Funding Number: RFA DK 20 003 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Liver Cirrhosis Network: Scientific and Data Coordination Center (U24 Clinical Trial Optional) Apply for RFA DK 20 004 Funding Number: RFA DK 20 004 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional) Apply for RFA DK 20 022 Funding Number: RFA DK 20 022 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Toward ElucidAting MechanismS Contributing to HIV Reservoirs in NIDDK-relevant Tissues (Cure TEAMS) (R01 Clinical Trial Optional) Apply for RFA DK 20 023 Funding Number: RFA DK 20 023 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Limited Competition for the Continuation of the Urinary Stone Disease Research Network (USDRN) Clinical Centers (U01 Clinical Trial Required) Apply for RFA DK 20 506 Funding Number: RFA DK 20 506 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $400,000 |
| Limited Competition for the Continuation of the Urinary Stone Disease Research Network (USDRN) Scientific Data Research Center (U24 Clinical Trial Required) Apply for RFA DK 20 507 Funding Number: RFA DK 20 507 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $700,000 |
| Limited Competition for Continuation of the Integrated Islet Distribution Program (U24 Clinical Trial Not Allowed) Apply for RFA DK 20 509 Funding Number: RFA DK 20 509 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $2,000,000 |
| Limited Competition for the Continuation of Clinical Centers to Investigate the Pathogenesis, Etiology, and Treatment of Gastroparesis through the NIDDK Gastroparesis Consortium (U01 Clinical Trial Optional) Apply for RFA DK 20 504 Funding Number: RFA DK 20 504 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $250,000 |
| Limited Competition for the Continuation of the Scientific Data Research Center (SDRC) for the NIDDK Gastroparesis Consortium (U24 Clinical Trial Optional) Apply for RFA DK 20 505 Funding Number: RFA DK 20 505 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $1,000,000 |
| NIDDK Education Program Grants (R25 Clinical Trial Not Allowed) Apply for PAR 21 034 Funding Number: PAR 21 034 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $100,000 |
| Understanding the Cellular and Molecular Mechanisms of Gastroparesis in Adults and Children (R01 Clinical Trial Not Allowed) Apply for RFA DK 20 030 Funding Number: RFA DK 20 030 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $250,000 |
| Exploratory Centers for Interdisciplinary Research in Benign Urology (P20 Clinical Trial Optional) Apply for RFA DK 20 033 Funding Number: RFA DK 20 033 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Diabetes Research Centers (P30 Clinical Trial Optional) Apply for RFA DK 20 025 Funding Number: RFA DK 20 025 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| GenitoUrinary Development Molecular Anatomy Project (GUDMAP) - Atlas Projects (U01 Clinical Trial Not Allowed) Apply for RFA DK 20 013 Funding Number: RFA DK 20 013 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 20 212", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.